Zymenex A/S

April 2008: Zymenex, a Danish clinical-stage orphan drug development company has sold the phase II project Metazyme targeting MLD (Metachromatic Leucodystrophy) to British Shire Pharmaceuticals for USD 135 million. The transaction takes up a first place in Europe among published up-front deals in 2008.

www.zymenex.com
Sten Verland

Partner

Mobile: +45 24 22 19 69
Email Click here to contact